ACTEMRA 162 MG / 0.9 ML — DIN 02424770
TOCILIZUMAB : 162 MG / 0.9 ML · HOFFMANN-LA ROCHE LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ACTEMRA?
ACTEMRA 162 MG / 0.9 ML contains TOCILIZUMAB : 162 MG / 0.9 ML. It is listed in the Health Canada Drug Product Database under DIN 02424770, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 30-May-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACTEMRA used for?
ACTEMRA (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis; for the treatment of giant cell arteritis (GCA) in adult patients; for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have responded inadequately to previous therapy with DMARDs; for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with one or more non-steroidal anti-inflammatory drugs and systemic corticosteroids; for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS); and for the treatment of hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids, and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Tocilizumab cost around the world?
Tocilizumab is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 3 | 90 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 18 | NOK███.██ |
| Hungary | producer price (ex-factory) | 9 | 16 | HUF███.██ |
| Czechia | max producer price (ex-factory) | 3 | 15 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 14 | 14 | EUR███.██ |
| Italy | ex-factory (classe H) | 14 | 14 | EUR███.██ |
| Slovakia | categorised final price | 8 | 14 | EUR███.██ |
| Saudi Arabia | public | 7 | 9 | SAR███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| Bahrain | retail (max) | 1 | 4 | BHD███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Romania | max producer price | 2 | 4 | RON███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
213 pack listings across 79 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Tocilizumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Tocilizumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Tocilizumab, across 10 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 5 | 5 | TYENNE | Sourceable in Canada |
| HOFFMANN-LA ROCHE LIMITED | 5 | 5 | ACTEMRA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 162 MG / 0.9 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | tocilizumab for injection (20 mg/mL) vials, tocilizumab injection (162 mg/ 0.9 mL) pre-filled syringe and Autoinjector |
| Storage | It can be stored for 24 hours at 30 °C and up to 2 weeks in a refrigerator at 2 °C - 8°C. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Tocilizumab |
|---|---|
| ATC code | L04AC07 |
| AHFS class | 90:24.20.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02424770 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2424770 |
| Brand name | ACTEMRA |
| Generic / active ingredient | TOCILIZUMAB : 162 MG / 0.9 ML |
| Market authorization holder | HOFFMANN-LA ROCHE LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L04AC07 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AC |
| Current status | MARKETED |
| Status date | 30-May-2014 |
| Original market date | 2014-05-30 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACTEMRA | 80 MG / 4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02350092 |
| ACTEMRA | 200 MG / 10 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02350106 |
| ACTEMRA | 400 MG / 20 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02350114 |
| ACTEMRA | 162 MG / 0.9 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02483327 |
| TYENNE | 80 MG / 4 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02552450 |
| TYENNE | 200 MG / 10 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02552469 |
| TYENNE | 400 MG / 20 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02552477 |
| TYENNE | 162 MG / 0.9 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02552485 |
| TYENNE | 162 MG / 0.9 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02552493 |
2 · Same class — other molecules in ATC L04AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ustekinumab | FINLIUS · FINLIUS I.V. · JAMTEKI · JAMTEKI I.V. · +10 more | 25 | 24 | Yes |
| Tocilizumab | ACTEMRA · TYENNE | 10 | 10 | Yes |
| Mirikizumab | OMVOH | 7 | 7 | Yes |
| Rizankizumab | SKYRIZI | 7 | 5 | Yes |
| Secukinumab | COSENTYX | 6 | 5 | Yes |
| Guselkumab | TREMFYA · TREMFYA I.V. · TREMFYA ONE-PRESS | 5 | 4 | Yes |
| Bimekizumab | BIMZELX | 4 | 4 | Yes |
| Sarilumab | KEVZARA | 4 | 3 | Yes |
| Siltuximab | SYLVANT | 2 | 2 | Yes |
| Spesolimab | SPEVIGO | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACTEMRA called?
Also recorded in Canada as: 0.9 ML tocilizumab 180 MG/ML Prefilled Syringe [Actemra] (US), 4 ML tocilizumab 20 MG/ML Injection [Actemra] (US), 10 ML tocilizumab 20 MG/ML Injection [Actemra] (US), 20 ML tocilizumab 20 MG/ML Injection [Actemra] (US), 0.9 ML tocilizumab 180 MG/ML Auto-Injector [Actemra] (US), 4 ML tocilizumab-aazg 20 MG/ML Injection [Tyenne] (US), 10 ML tocilizumab-aazg 20 MG/ML Injection [Tyenne] (US), 20 ML tocilizumab-aazg 20 MG/ML Injection [Tyenne] (US), 10 ML tocilizumab-bavi 20 MG/ML Injection [Tofidence] (US), 20 ML tocilizumab-bavi 20 MG/ML Injection [Tofidence] (US), 4 ML tocilizumab-bavi 20 MG/ML Injection [Tofidence] (US), 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [Tyenne] (US), 0.9 ML tocilizumab-aazg 180 MG/ML Prefilled Syringe [Tyenne] (US), 0.9 ML tocilizumab-anoh 180 MG/ML Prefilled Syringe [Avtozma] (US), 0.9 ML tocilizumab-anoh 180 MG/ML Auto-Injector [Avtozma] (US).
The same molecule, Tocilizumab, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actemra ACTPen | Latin | Australia |
| Actemra Subcutaneous Injection | Latin | Australia |
| RoActemra | Latin | Czechia, Norway |
| Tyenne | Latin | Czechia, Norway, Saudi Arabia |
| Avtozma | Latin | Czechia, Norway |
| Actemra SC | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.